Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the first major application of AlphaProteo by the end of 2024?
Drug Development • 25%
Disease Diagnosis • 25%
Biosensor Technology • 25%
Other • 25%
Official announcements from Google DeepMind or partnering organizations
Google DeepMind Unveils AlphaProteo for High-Strength Protein Binders with 3-300x Better Affinities
Sep 5, 2024, 03:24 PM
Google DeepMind has unveiled AlphaProteo, a new AI system designed to create novel, high-strength protein binders that target specific molecules. AlphaProteo achieves 3-300x better binding affinities and success rates on 7 targets compared to existing methods, making it a significant advancement in drug development, disease diagnosis, and biosensor technology. This system could accelerate the understanding of biological processes and aid in the development of new therapies. AlphaProteo's capabilities, trained on synthetic data from AlphaFold, are expected to outperform existing methods in binding proteins, potentially revolutionizing the field of biotechnology.
View original story
Drug Development • 25%
Agricultural Biotechnology • 25%
Industrial Enzymes • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Smartphones • 25%
Data Centers • 25%
AI Models • 25%
Other • 25%
Drug Discovery • 25%
Agriculture • 25%
Climate Science • 25%
Other • 25%
Highly Positive • 25%
Moderately Positive • 25%
Neutral • 25%
Negative • 25%
Pfizer • 25%
Moderna • 25%
Novartis • 25%
Other • 25%
Cancer treatment • 25%
Infectious diseases • 25%
Neurological disorders • 25%
Other • 25%
No • 50%
Yes • 50%
Pfizer • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%